116 related articles for article (PubMed ID: 20460535)
21. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
[TBL] [Abstract][Full Text] [Related]
22. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
23. Proteasome inhibition: mechanism of action.
DeMartino GN
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
[TBL] [Abstract][Full Text] [Related]
24. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Sorolla A; Yeramian A; Dolcet X; Pérez de Santos AM; Llobet D; Schoenenberger JA; Casanova JM; Soria X; Egido R; Llombart A; Vilella R; Matias-Guiu X; Marti RM
Br J Dermatol; 2008 Mar; 158(3):496-504. PubMed ID: 18205878
[TBL] [Abstract][Full Text] [Related]
25. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Small GW; Shi YY; Edmund NA; Somasundaram S; Moore DT; Orlowski RZ
Mol Pharmacol; 2004 Dec; 66(6):1478-90. PubMed ID: 15448190
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
27. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
28. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
29. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
[TBL] [Abstract][Full Text] [Related]
30. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
[TBL] [Abstract][Full Text] [Related]
31. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Teraishi F; Guo W; Zhang L; Dong F; Davis JJ; Sasazuki T; Shirasawa S; Liu J; Fang B
Cancer Res; 2006 Jun; 66(12):6072-9. PubMed ID: 16778179
[TBL] [Abstract][Full Text] [Related]
32. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.
Lee C; Waldman T
Cancer Biol Ther; 2003; 2(6):700-1. PubMed ID: 14688480
[No Abstract] [Full Text] [Related]
33. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death.
Brohem CA; Massaro RR; Tiago M; Marinho CE; Jasiulionis MG; de Almeida RL; Rivelli DP; Albuquerque RC; de Oliveira TF; de Melo Loureiro AP; Okada S; Soengas MS; de Moraes Barros SB; Maria-Engler SS
Pigment Cell Melanoma Res; 2012 May; 25(3):354-69. PubMed ID: 22372875
[TBL] [Abstract][Full Text] [Related]
34. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Fernández Y; Miller TP; Denoyelle C; Esteban JA; Tang WH; Bengston AL; Soengas MS
J Biol Chem; 2006 Jan; 281(2):1107-18. PubMed ID: 16278210
[TBL] [Abstract][Full Text] [Related]
35. The proteasome.
Dalton WS
Semin Oncol; 2004 Dec; 31(6 Suppl 16):3-9; discussion 33. PubMed ID: 15799238
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Kandasamy K; Kraft AS
Mol Cancer Ther; 2008 May; 7(5):1091-100. PubMed ID: 18483298
[TBL] [Abstract][Full Text] [Related]
37. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
38. Targeting GRP78 to enhance melanoma cell death.
Martin S; Hill DS; Paton JC; Paton AW; Birch-Machin MA; Lovat PE; Redfern CP
Pigment Cell Melanoma Res; 2010 Oct; 23(5):675-82. PubMed ID: 20546536
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells.
Qi W; White MC; Choi W; Guo C; Dinney C; McConkey DJ; Siefker-Radtke A
PLoS One; 2013; 8(7):e69509. PubMed ID: 23874968
[TBL] [Abstract][Full Text] [Related]
40. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
Fleming JA; Lightcap ES; Sadis S; Thoroddsen V; Bulawa CE; Blackman RK
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1461-6. PubMed ID: 11830665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
